Triple
T22943650
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Vivek Ramaswamy |
E569805
|
entity |
| Predicate | founded |
P104
|
FINISHED |
| Object | Roivant Sciences |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Roivant Sciences | Statement: [Vivek Ramaswamy, founded, Roivant Sciences]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Roivant Sciences Context triple: [Vivek Ramaswamy, founded, Roivant Sciences]
-
A.
Flagship Pioneering
Flagship Pioneering is a venture creation firm and life sciences investment company known for founding and building innovative biotechnology companies, including Moderna.
-
B.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
C.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
D.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
E.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Roivant Sciences Target entity description: Roivant Sciences is a biopharmaceutical company known for acquiring and developing underutilized drug candidates through a portfolio of specialized subsidiary firms.
-
A.
Flagship Pioneering
Flagship Pioneering is a venture creation firm and life sciences investment company known for founding and building innovative biotechnology companies, including Moderna.
-
B.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
C.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
D.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
E.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e24590862c8190858f180ad302adab |
completed | April 17, 2026, 2:37 p.m. |
| NER | Named-entity recognition | batch_69f1819b65dc8190b9456346e7284ddf |
completed | April 29, 2026, 3:57 a.m. |
Created at: April 17, 2026, 3:45 p.m.